Comments
Hikal on Thursday said its pharmaceutical facility at Panoli, Gujarat, has received the green signal from the USFDA. The US drug authority’s inspection concluded with zero Form 483 observations. The Establishment Inspection Report received on December 12 classified the facility under No Action Indicated (NAI) for Current Good Manufacturing Practices (CGMP) compliance, Hikal said. The inspection was carried out between September 9 and 13.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.